



## **Michael Satlin, MD**

Infectious Diseases Physician and  
Associate Professor of Medicine and of  
Pathology and Laboratory Medicine

**Weill Cornell Medicine**

*Carbapenemases in XDR Pseudomonas*

Dr. Michael Satlin an infectious diseases physician and Associate Professor of Medicine and of Pathology and Laboratory Medicine at Weill Cornell Medicine. He is the Clinical Director of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell. He completed medical school at the University of Virginia School of Medicine and internal medicine residency and infectious diseases fellowship training at NewYork-Presbyterian Hospital/Weill Cornell. His research focuses on the epidemiology, prevention, and treatment of multidrug-resistant Gram-negative infections, with a focus on immunocompromised hosts. He has authored or co-authored over 100 peer-reviewed manuscripts. He is Associate Editor of Journal of Antimicrobial Chemotherapy-Antimicrobial Resistance, serves on the Editorial (Advisory) Boards of Journal of Clinical Microbiology, Clinical Infectious Diseases and Open Forum Infectious Diseases. He is a Member of the Clinical and Laboratory Standards Institute's (CLSI) Subcommittee on Antimicrobial Susceptibility Testing and Co-Chair of its Breakpoint Working Group. He also serves on multiple committees for NIAID's Antibacterial Resistance Leadership Group.